好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Argatroban Plus Antiplatelet Therapy Versus Antiplatelet Alone in Acute Ischemic Stroke: A GRADE Assessment Systematic Review and Meta-analysis.
Cerebrovascular Disease and Interventional Neurology
P3 - Poster Session 3 (5:00 PM-6:00 PM)
5-011

This meta-analysis compares the efficacy and safety of combining argatroban with antiplatelet therapy versus antiplatelet therapy alone.
Acute ischemic stroke (AIS) is a major global cause of disability and mortality. Although antiplatelet therapy is commonly used, its effectiveness is limited. Argatroban, a direct thrombin inhibitor, offers potential benefits for AIS patients.
This study was conducted according to PRISMA guidelines. PubMed, Scopus, Cochrane, and Web of Science were searched up to May 5, 2025. Primary outcomes included the modified Rankin Scale (mRS) and the National Institutes of Health Stroke Scale (NIHSS). Secondary outcomes included early neurological deterioration (END) and safety outcomes.

18 studies with a total of 11,781 patients were included in our study. Combined therapy significantly improved functional outcomes: mRS 0-2 (RR = 1.07, 95% CI [1.03–1.11], p = 0.001) and mRS 0-1 (RR = 1.21, 95% CI [1.06–1.38], p = 0.004). Argatroban also reduced the risk of END (RR = 0.49, 95% CI [0.32–0.76], p = 0.001) and overall NIHSS scores (MD = -0.55, 95% CI [-0.99 to -0.10], p = 0.02). No significant differences were found in safety outcomes or mortality.

Argatroban combined with antiplatelet therapy enhances neurological and functional recovery in AIS without elevating bleeding or mortality risks. This dual approach shows promise as a treatment strategy, though larger randomized trials are needed to validate its benefits.
Authors/Disclosures
Ahmed Abbas
PRESENTER 		Ahmed Abbas has nothing to disclose.
Rashad G. Mohamed, MBBS Dr. Mohamed has nothing to disclose.
Yousef A. Hawas Mr. Hawas has a non-compensated relationship as a Faculty with 好色先生 Institution (AANI); NeuroBytes: Medical Students Series that is relevant to AAN interests or activities.
Mohamed Ellebedy, MD Dr. Ellebedy has nothing to disclose.
Mohamed Abo-elsoad, Medical student Dr. Abo-elsoad has nothing to disclose.
Magdy H. Shehab, Sr., MD Dr. Shehab has nothing to disclose.
Amir H. Hegazi, MBBS Mr. Hegazi has nothing to disclose.
Hussien O. Hussien, MBBS Dr. Hussien has nothing to disclose.
sarah amro, MD Dr. amro has nothing to disclose.
Kareem Khalefa, MD Dr. Khalefa has nothing to disclose.
Moaz E. Abouelmagd, MD Dr. Abouelmagd has nothing to disclose.
Ahmed Negida, MD, PhD (Virginia Commonwealth University) Dr. Negida has nothing to disclose.
Muataz O. Kashbour, MBBS Dr. Kashbour has nothing to disclose.